LFCR

Business Context and Reporting Period

Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and sodium hyaluronate (HA) manufacturing. This Form 10-Q covers the fiscal quarter ended August 25, 2024. The Company operates as a single reportable segment and is classified as an Accelerated Filer and Smaller Reporting Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Stability: Total revenue increased slightly by 1% ($183,000). This was driven by a $1.5 million increase in HA manufacturing revenue due to shipment timing, partially offset by a $1.3 million decrease in CDMO revenue as a customer worked down inventory.
• Gross Margin Expansion: Gross profit increased 97% to $5.4 million, with margins improving from 11.1% to 21.8%. This was primarily due to favorable sales mix and price increases in CDMO services, partially offset by inventory write-downs in HA manufacturing.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses surged 61% to $14.8 million. This increase was largely driven by non-recurring professional fees of $4.7 million, including $2.4 million in audit fees (due to an auditor switch) and $2.3 million in legal fees related to civil litigation and a stockholder activist settlement.
• Interest Expense: Net interest expense increased 36% to $5.4 million, primarily due to amortization of debt discounts on the Alcon term loan and reduced capitalized interest.
• Discontinued Operations: The prior year period included $1.9 million of income from discontinued operations (Curation Foods insurance settlement), which was absent in the current period.

Outlook, Risks, and Unusual Items

• Liquidity and Capital Resources: Cash decreased by $2.9 million during the quarter. The Company has approximately $4.5 million available under its Revolving Credit Facility. Management believes existing cash, operating cash flow, and a subsequent equity offering (see below) will fund operations for at least 12 months.
• Subsequent Equity Offering: On October 3, 2024, the Company closed a Securities Purchase Agreement to sell approximately 5.9 million shares of common stock for gross proceeds of approximately $24.3 million ($4.10 per share).
• Legal and Regulatory Risks:
  • SEC Subpoena: The Company is responding to an SEC subpoena issued in February 2024 regarding a financial statement restatement.
  • Internal Controls: Disclosure controls and procedures were deemed not effective as of August 25, 2024, due to material weaknesses in internal control over financial reporting. Remediation plans are underway.
  • Registration Rights Penalties: The Company incurred $275,000 in monetary penalties and $95,000 in interest for delinquent SEC filings under the Registration Rights Agreement.
  • Landlord Disputes: Ongoing civil actions regarding unpaid rent for former Curation Foods properties.
• Debt Derivative Liability: A gain of $0.9 million was recognized from the change in fair value of a debt derivative liability related to the Alcon term loan.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $24.3 million proceeds from the October 2024 equity offering combined with the $4.5 million revolver availability to cover the high burn rate and debt service obligations.
• Debt Covenants: Confirm continued compliance with financial covenants under the Term Loan and Revolving Credit Facility, given the high effective interest rate (22.5% on Term Loan).
• Internal Control Remediation: Monitor the progress of remediation for material weaknesses in internal controls, as this impacts the reliability of future financial reporting.
• Legal Exposure: Assess the potential financial impact of the SEC investigation, the Yucatan Foods litigation, and landlord disputes, noting that ultimate outcomes are uncertain.
• Customer Concentration: Review the dependency on top customers, as two customers accounted for 32% and 24% of revenue in the quarter.